Vaccines After COVID: Biopharma's Renewed Public Health and Commercial Push

Posted on by admin

At the Financial Times’ Global Pharma and Biotech Summit 2024, a panel discussed the potential of mRNA technology in developing cancer vaccines amid distrust from the public.

Leave a Reply

Your email address will not be published. Required fields are marked *